NZ568546A - Immunomodulatory properties of multipotent adult progenitor cells and uses thereof - Google Patents

Immunomodulatory properties of multipotent adult progenitor cells and uses thereof

Info

Publication number
NZ568546A
NZ568546A NZ568546A NZ56854606A NZ568546A NZ 568546 A NZ568546 A NZ 568546A NZ 568546 A NZ568546 A NZ 568546A NZ 56854606 A NZ56854606 A NZ 56854606A NZ 568546 A NZ568546 A NZ 568546A
Authority
NZ
New Zealand
Prior art keywords
cells
subject
mapcs
administered
treat
Prior art date
Application number
NZ568546A
Other languages
English (en)
Inventor
Robert Deans
T Hof Wouter Van
Richard Maziarz
Magdalena Kovacsovics
Philip Streeter
Original Assignee
Athersys Inc
Univ Oregon Health & Science
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Athersys Inc, Univ Oregon Health & Science filed Critical Athersys Inc
Priority to NZ59602206A priority Critical patent/NZ596022A/xx
Publication of NZ568546A publication Critical patent/NZ568546A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Transplantation (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Materials For Medical Uses (AREA)
NZ568546A 2005-11-09 2006-11-09 Immunomodulatory properties of multipotent adult progenitor cells and uses thereof NZ568546A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ59602206A NZ596022A (en) 2005-11-09 2006-11-09 Immunomodulatory properties of multipotent adult progenitor cells and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/269,736 US8147824B2 (en) 1999-08-05 2005-11-09 Immunomodulatory properties of multipotent adult progenitor cells and uses thereof
PCT/US2006/043804 WO2007056578A1 (en) 2005-11-09 2006-11-09 Immunomodulatory properties of multipotent adult progenitor cells and uses thereof

Publications (1)

Publication Number Publication Date
NZ568546A true NZ568546A (en) 2012-06-29

Family

ID=37808258

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ568546A NZ568546A (en) 2005-11-09 2006-11-09 Immunomodulatory properties of multipotent adult progenitor cells and uses thereof
NZ59602206A NZ596022A (en) 2005-11-09 2006-11-09 Immunomodulatory properties of multipotent adult progenitor cells and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ59602206A NZ596022A (en) 2005-11-09 2006-11-09 Immunomodulatory properties of multipotent adult progenitor cells and uses thereof

Country Status (19)

Country Link
US (6) US8147824B2 (enExample)
EP (3) EP3808373A1 (enExample)
JP (3) JP5399709B2 (enExample)
KR (1) KR101423786B1 (enExample)
CN (3) CN101336112B (enExample)
AU (1) AU2006311418B2 (enExample)
BR (1) BRPI0618486B1 (enExample)
CA (3) CA2628254C (enExample)
DK (2) DK1951294T3 (enExample)
ES (2) ES2778424T3 (enExample)
HU (1) HUE055956T2 (enExample)
IL (5) IL191317A (enExample)
LT (1) LT1951294T (enExample)
NZ (2) NZ568546A (enExample)
PH (2) PH12021551194A1 (enExample)
PL (2) PL2684571T3 (enExample)
PT (2) PT2684571T (enExample)
RU (1) RU2497530C2 (enExample)
WO (1) WO2007056578A1 (enExample)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8252280B1 (en) 1999-08-05 2012-08-28 Regents Of The University Of Minnesota MAPC generation of muscle
US7015037B1 (en) 1999-08-05 2006-03-21 Regents Of The University Of Minnesota Multiponent adult stem cells and methods for isolation
US8147824B2 (en) * 1999-08-05 2012-04-03 Athersys, Inc. Immunomodulatory properties of multipotent adult progenitor cells and uses thereof
US10638734B2 (en) 2004-01-05 2020-05-05 Abt Holding Company Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof
US7311905B2 (en) 2002-02-13 2007-12-25 Anthrogenesis Corporation Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
WO2002046373A1 (en) 2000-12-06 2002-06-13 Hariri Robert J Method of collecting placental stem cells
NZ527849A (en) * 2001-02-14 2006-09-29 Anthrogenesis Corp Post-partum mammalian placenta, its use and placental stem cells therefrom
CA2438501C (en) * 2001-02-14 2014-09-16 Leo T. Furcht Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof
NZ528035A (en) * 2001-02-14 2005-07-29 Robert J Hariri Renovation and repopulation of decellularized tissues and cadaveric organs by stem cells
DE10144326B4 (de) * 2001-09-10 2005-09-22 Siemens Ag Verfahren und System zur Überwachung eines Reifenluftdrucks
WO2005003317A2 (en) * 2003-07-01 2005-01-13 Regents Of The University Of Minnesota Engineered blood vessels
NZ597304A (en) 2005-10-13 2013-06-28 Anthrogenesis Corp Immunomodulation using placental stem cells
US10117900B2 (en) 2005-11-09 2018-11-06 Athersys, Inc. MAPC treatment of brain injuries and diseases
US11000546B2 (en) 2005-11-09 2021-05-11 Athersys, Inc. Immunomodulatory properties of MAPCs and uses thereof
DK2471904T3 (en) 2005-12-29 2019-02-18 Celularity Inc Placenta stem cell populations
JP2009521930A (ja) 2005-12-29 2009-06-11 アントフロゲネシス コーポレーション 胎盤幹細胞及び第２供給源由来幹細胞の共存培養
ES2415855T3 (es) 2006-01-13 2013-07-29 Osiris Therapeutics, Inc. Células troncales mesenquimatosas que expresan el receptor de TNF
US11992507B2 (en) 2006-01-23 2024-05-28 Abt Holding Company MAPC therapeutics without adjunctive immunosuppressive treatment
US20110171182A1 (en) * 2006-03-23 2011-07-14 Pluristem Ltd. Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy
US7993918B2 (en) 2006-08-04 2011-08-09 Anthrogenesis Corporation Tumor suppression using placental stem cells
CA2850793A1 (en) 2006-10-23 2008-05-02 Anthrogenesis Corporation Methods and compositions for treatment of bone defects with placental cell populations
AU2007321928A1 (en) * 2006-11-24 2008-05-29 Regents Of The University Of Minnesota Endodermal progenitor cells
HRP20130765T1 (hr) 2007-02-12 2013-10-25 Anthrogenesis Corporation Lijeäśenje protuupalnih bolesti putem matiäśnih stanica posteljice
AU2008307633C1 (en) 2007-09-28 2015-04-30 Celularity Inc. Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
CA2743682A1 (en) 2007-11-30 2009-06-11 New York Medical College Methods of reducing transplant rejection and cardiac allograft vasculopathy by implanting autologous stem cells
WO2009073618A2 (en) * 2007-11-30 2009-06-11 New York Medical College Compositions comprising hdac inhibitors and methods of their use in restoring stem cell function and preventing heart failure
US8512696B2 (en) 2007-11-30 2013-08-20 Autologous, Llc Methods of isolating non-senescent cardiac stem cells and uses thereof
WO2009073518A1 (en) * 2007-11-30 2009-06-11 New York Medical College Methods of isolating non-senescent cardiac stem cells and uses thereof
EP2227238A2 (en) 2007-11-30 2010-09-15 New York Medical College Compositions comprising vascular and myocyte progenitor cells and methods of their use
CA2712496C (en) 2008-01-18 2021-01-12 Wei-Shou Hu Stem cell aggregates and methods for making and using
MX339624B (es) 2008-08-20 2016-06-02 Anthrogenesis Corp Composiciones mejoradas de celulas y metodos para preparar las mismas.
JP5950577B2 (ja) 2008-08-20 2016-07-13 アンスロジェネシス コーポレーション 単離胎盤細胞を使用した脳卒中の治療
EP2331109B1 (en) 2008-08-22 2013-05-29 Anthrogenesis Corporation Methods and compositions for treatment of bone defects with placental cell populations
CA2743566C (en) 2008-11-19 2021-11-09 Anthrogenesis Corporation Amnion derived adherent cells
AU2010276201B2 (en) 2009-07-21 2013-10-17 Healios K.K. Use of stem cells to reduce leukocyte extravasation
SG10201404281YA (en) * 2009-07-21 2014-09-26 Abt Holding Co Use of stem cells to reduce leukocyte extravasation
DK3284818T3 (da) 2010-01-26 2022-06-20 Celularity Inc Behandling af knoglerelateret kræft ved hjælp af placenta stamceller
TW201703777A (zh) 2010-04-07 2017-02-01 安瑟吉納西斯公司 利用胎盤幹細胞之血管新生
NZ602798A (en) 2010-04-08 2014-10-31 Anthrogenesis Corp Treatment of sarcoidosis using placental stem cells
SG10201913920PA (en) 2010-05-12 2020-03-30 Abt Holding Co Modulation of splenocytes in cell therapy
WO2012009422A1 (en) 2010-07-13 2012-01-19 Anthrogenesis Corporation Methods of generating natural killer cells
US8642027B2 (en) 2010-09-01 2014-02-04 Stemnion, Inc. Compositions and methods for modulating ischemic injury
WO2012048298A2 (en) 2010-10-08 2012-04-12 Caridianbct, Inc. Methods and systems of growing and harvesting cells in a hollow fiber bioreactor system with control conditions
US20120087868A1 (en) 2010-10-08 2012-04-12 Gabriele Todd Nanoparticle-loaded cells
AR093183A1 (es) 2010-12-31 2015-05-27 Anthrogenesis Corp Aumento de la potencia de celulas madre de placenta usando moleculas de arn moduladoras
CN104220081A (zh) 2011-06-01 2014-12-17 人类起源公司 利用胎盘干细胞治疗疼痛
KR102073530B1 (ko) * 2011-06-06 2020-02-04 리제네시스 비브이비에이 중공 섬유 생물 반응기에서의 줄기 세포의 확장
WO2013055476A1 (en) 2011-09-09 2013-04-18 Anthrogenesis Corporation Treatment of amyotrophic lateral sclerosis using placental stem cells
WO2013081436A1 (ko) * 2011-12-01 2013-06-06 주식회사 알앤엘바이오 줄기세포를 젊게 만들기 위한 배지 조성물
ES2833280T3 (es) 2012-01-13 2021-06-14 Massachusetts Gen Hospital Células progenitoras pulmonares humanas aisladas y usos de las mismas
WO2014015318A1 (en) * 2012-07-19 2014-01-23 Bluebird Bio, Inc. Soluble compounds for improved gene therapy methods
WO2014123879A1 (en) 2013-02-05 2014-08-14 Anthrogenesis Corporation Natural killer cells from placenta
AU2014217615B2 (en) 2013-02-12 2018-11-15 Reneuron Limited Method of producing microparticles
AU2014250761B2 (en) * 2013-04-12 2019-02-28 Robert J. Deans Improving organs for transplantation
AU2014266935B2 (en) * 2013-04-30 2020-06-11 Katholieke Universiteit Leuven Cell therapy for myelodysplastic syndromes
WO2015073918A1 (en) 2013-11-16 2015-05-21 Terumo Bct, Inc. Expanding cells in a bioreactor
ITFI20130303A1 (it) * 2013-12-24 2015-06-25 Azienda Ospedaliero Universitaria M Eyer Metodica per l¿isolamento, purificazione ed amplificazione di progenitori renali cd133+cd24+ dalle urine di pazienti affetti da malattie renali.
US11008547B2 (en) 2014-03-25 2021-05-18 Terumo Bct, Inc. Passive replacement of media
WO2016049421A1 (en) 2014-09-26 2016-03-31 Terumo Bct, Inc. Scheduled feed
RU2580640C1 (ru) * 2014-12-25 2016-04-10 Федеральное государственное бюджетное учреждение "Федеральный научный центр трансплантологии и искусственных органов имени академика В.И. Шумакова" Министерства здравоохранения Российской Федерации Способ профилактики гуморального отторжения при аво-несовместимой трансплантации печени детям раннего возраста
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
HK1256413A1 (zh) 2016-01-21 2019-09-20 Abt Holding Company 用於伤口癒合的干细胞
US11965175B2 (en) 2016-05-25 2024-04-23 Terumo Bct, Inc. Cell expansion
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US10767164B2 (en) 2017-03-30 2020-09-08 The Research Foundation For The State University Of New York Microenvironments for self-assembly of islet organoids from stem cells differentiation
US11629332B2 (en) 2017-03-31 2023-04-18 Terumo Bct, Inc. Cell expansion
US12234441B2 (en) 2017-03-31 2025-02-25 Terumo Bct, Inc. Cell expansion
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
JP7102397B2 (ja) 2017-04-03 2022-07-19 株式会社カネカ 間葉系幹細胞を含む細胞集団とその製造方法、及び医薬組成物
CN107714726A (zh) * 2017-10-16 2018-02-23 中国科学院广州生物医药与健康研究院 一种重塑骨髓微环境的方法
CN112004923A (zh) 2017-11-22 2020-11-27 迈索布拉斯特国际有限公司 细胞组合物及治疗方法
WO2019132026A1 (ja) 2017-12-28 2019-07-04 株式会社カネカ 接着性幹細胞を含む細胞集団とその製造方法、及び医薬組成物
EP3733838A4 (en) 2017-12-28 2021-11-03 Kaneka Corporation CELL POPULATION WITH ADHESIVE STEM CELLS, METHOD FOR MANUFACTURING SUCH CELL POPULATION AND PHARMACEUTICAL COMPOSITION
CN109735611A (zh) * 2018-12-19 2019-05-10 珠海铂华生物工程有限公司 一种用于检测骨髓衰竭综合征的基因组合、引物库、构建高通量测序文库的方法及其应用
JPWO2020184350A1 (enExample) 2019-03-08 2020-09-17
GB2619893A (en) 2021-03-23 2023-12-20 Terumo Bct Inc Cell capture and expansion
JP2024537531A (ja) 2021-11-05 2024-10-10 株式会社ヘリオス 拡大培養したイヌ前駆細胞および関連する方法
US12209689B2 (en) 2022-02-28 2025-01-28 Terumo Kabushiki Kaisha Multiple-tube pinch valve assembly
USD1099116S1 (en) 2022-09-01 2025-10-21 Terumo Bct, Inc. Display screen or portion thereof with a graphical user interface for displaying cell culture process steps and measurements of an associated bioreactor device
WO2024046355A1 (en) * 2022-09-02 2024-03-07 Medical And Pharmaceutical Industry Technology And Development Center Use of composition including mesenchymal stem cells for alleviating myelofibrosis

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4353888A (en) 1980-12-23 1982-10-12 Sefton Michael V Encapsulation of live animal cells
US4749620A (en) 1984-02-15 1988-06-07 Massachusetts Institute Of Technology Encapsulated active material system
US4744933A (en) 1984-02-15 1988-05-17 Massachusetts Institute Of Technology Process for encapsulation and encapsulated active material system
JPH0628570B2 (ja) 1986-02-13 1994-04-20 雪印乳業株式会社 カプセル体の製造方法及び装置
EP0301777A1 (en) 1987-07-28 1989-02-01 Queen's University At Kingston Multiple membrane microencapsulation
US5089272A (en) 1989-03-29 1992-02-18 Snow Brand Milk Products Co., Ltd. Process for producing capsules having a permeability-controllable membrane
US5084350A (en) 1990-02-16 1992-01-28 The Royal Institution For The Advance Of Learning (Mcgill University) Method for encapsulating biologically active material including cells
US5578442A (en) 1992-03-23 1996-11-26 Vivorx, Inc. Graft copolymers of polycationic species and water-soluble polymers, and use therefor
US6270766B1 (en) * 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
CA2169292C (en) 1993-08-12 2010-11-23 E. Edward Baetge Improved compositions and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules
JPH07316051A (ja) 1994-05-23 1995-12-05 Kanegafuchi Chem Ind Co Ltd 免疫抑制剤としてのベルベリン
IN184685B (enExample) * 1996-02-14 2000-09-23 Nat Inst Immunology
DK1007631T4 (da) * 1997-07-14 2009-04-27 Osiris Therapeutics Inc Hjertemuskelregeneration ved anvendelse af mesenkymale stamceller
US7514074B2 (en) * 1997-07-14 2009-04-07 Osiris Therapeutics, Inc. Cardiac muscle regeneration using mesenchymal stem cells
US20030103951A1 (en) 1997-07-14 2003-06-05 Osiris Therapeutics, Inc. Cardiac muscle regeneration using mesenchymal stem cells
AU1508899A (en) 1997-12-02 1999-06-16 Chong Kun Dang Corporation Pharmaceutical composition comprising cyclosporin solid-state microemulsion
EP1062321B1 (en) * 1998-03-13 2004-12-29 Osiris Therapeutics, Inc. Uses for humane non-autologous mesenchymal stem cells
US6368636B1 (en) * 1998-03-18 2002-04-09 Osiris Therapeutics, Inc. Mesenchymal stem cells for prevention and treatment of immune responses in transplantation
CA2320040C (en) * 1998-03-18 2007-05-22 Osiris Therapeutics, Inc. Mesenchymal stem cells for prevention and treatment of immune responses in transplantation
US6797269B2 (en) * 1998-04-03 2004-09-28 Osiris Therapeutics, Inc. Mesenchymal stem cells as immunosuppressants
AU757682B2 (en) * 1998-04-08 2003-02-27 Metabolix, Inc. Methods for separation and purification of biopolymers
CA2244554A1 (en) * 1998-07-30 2000-01-30 Vasogen Inc. Inhibition of graft versus host disease
US6060364A (en) * 1999-03-02 2000-05-09 Advanced Micro Devices, Inc. Fast Mosfet with low-doped source/drain
US7015037B1 (en) 1999-08-05 2006-03-21 Regents Of The University Of Minnesota Multiponent adult stem cells and methods for isolation
WO2005113748A2 (en) 2004-04-21 2005-12-01 Regents Of The University Of Minnesota Mapc generation of lung tissue
US7927587B2 (en) 1999-08-05 2011-04-19 Regents Of The University Of Minnesota MAPC administration for the treatment of lysosomal storage disorders
US8075881B2 (en) * 1999-08-05 2011-12-13 Regents Of The University Of Minnesota Use of multipotent adult stem cells in treatment of myocardial infarction and congestive heart failure
DK1226233T3 (da) 1999-08-05 2011-10-03 Abt Holding Co Multipotente voksne stamceller og fremgangsmåder til isolering heraf
US8147824B2 (en) 1999-08-05 2012-04-03 Athersys, Inc. Immunomodulatory properties of multipotent adult progenitor cells and uses thereof
US6685936B2 (en) * 1999-10-12 2004-02-03 Osiris Therapeutics, Inc. Suppressor cells induced by culture with mesenchymal stem cells for treatment of immune responses in transplantation
AU2002232405A1 (en) 2000-11-20 2002-05-27 California Institute Of Technology Artery smooth muscle- and vein smooth muscle-specific proteins and uses therefor
US20030044843A1 (en) 2001-01-09 2003-03-06 Mitsubishi Pharma Corporation Novel proteome analysis method and devices therefor
CA2438501C (en) 2001-02-14 2014-09-16 Leo T. Furcht Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof
US9969980B2 (en) 2001-09-21 2018-05-15 Garnet Biotherapeutics Cell populations which co-express CD49c and CD90
AU2003209259A1 (en) 2002-01-14 2003-07-30 The Board Of Trustees Of The University Of Illinois Novel mammalian multipotent stem cells and compositions, methods of preparation and methods of administration thereof
US20040037811A1 (en) 2002-08-22 2004-02-26 The Cleveland Clinic Foundation Stromal cell-derived factor-1 mediates stem cell homing and tissue regeneration in ischemic cardiomyopathy
US7105037B2 (en) 2002-10-31 2006-09-12 Advanced Technology Materials, Inc. Semiconductor manufacturing facility utilizing exhaust recirculation
WO2004069172A2 (en) 2003-01-30 2004-08-19 The Government of the United States of America as represented by the Department of Veterans Affairs Multilineage-inducible cells and uses thereof
WO2004099395A2 (en) 2003-05-08 2004-11-18 Cellartis Ab A method for the generation of neural progenitor cells
CA2530421C (en) * 2003-06-27 2015-04-21 Ethicon, Incorporated Repair and regeneration of ocular tissue using postpartum-derived cells
WO2005003320A2 (en) * 2003-07-02 2005-01-13 Regents Of The University Of Minnesota Neuronal differentiation of stem cells
AU2005331559B2 (en) 2005-05-05 2012-04-19 Regents Of The University Of Minnesota Use of NK cell inhibition to facilitate persistence of engrafted MHC-I negative cells
US20080311084A1 (en) 2005-05-05 2008-12-18 Verfaillie Catherine M Mapc Engraftment in the Hematopoietic System
TW200726474A (en) 2005-07-15 2007-07-16 Cognate Therapeutics Inc The immunophenotype and immunogenicity of human adipose derived cells
EP2368973A1 (en) 2005-10-13 2011-09-28 Anthrogenesis Corporation Production Of Oligodendrocytes From Placenta-Derived Stem Cells
US10117900B2 (en) 2005-11-09 2018-11-06 Athersys, Inc. MAPC treatment of brain injuries and diseases
US11000546B2 (en) 2005-11-09 2021-05-11 Athersys, Inc. Immunomodulatory properties of MAPCs and uses thereof
US11992507B2 (en) 2006-01-23 2024-05-28 Abt Holding Company MAPC therapeutics without adjunctive immunosuppressive treatment
US7993918B2 (en) 2006-08-04 2011-08-09 Anthrogenesis Corporation Tumor suppression using placental stem cells
HRP20130765T1 (hr) 2007-02-12 2013-10-25 Anthrogenesis Corporation Lijeäśenje protuupalnih bolesti putem matiäśnih stanica posteljice
US20120121545A1 (en) 2009-01-15 2012-05-17 Corestem Co., Ltd. Pharmaceutical Composition For Bone Disease Treatment Or Countering Inflammation, Comprising Cartilage Stem Cells As An Active Principle
EP2241617A1 (en) 2009-04-06 2010-10-20 Rijksuniversiteit Groningen Multipotent cells derived from blood and methods and uses related thereto

Also Published As

Publication number Publication date
CA3206592A1 (en) 2007-05-18
LT1951294T (lt) 2020-04-10
EP1951294A1 (en) 2008-08-06
IL191317A (en) 2015-03-31
JP2016135763A (ja) 2016-07-28
US20120135043A1 (en) 2012-05-31
IL249572B (en) 2020-08-31
JP5399709B2 (ja) 2014-01-29
US8147824B2 (en) 2012-04-03
DK1951294T3 (da) 2020-03-23
CN104873540B (zh) 2019-11-15
IL236832A (en) 2017-08-31
BRPI0618486B1 (pt) 2021-11-30
US9808485B2 (en) 2017-11-07
US20090104163A1 (en) 2009-04-23
CN104873540A (zh) 2015-09-02
ES2778424T3 (es) 2020-08-10
JP2009514979A (ja) 2009-04-09
IL289024A (en) 2022-02-01
HK1203058A1 (en) 2015-10-16
JP2013256510A (ja) 2013-12-26
HK1214166A1 (zh) 2016-07-22
HUE055956T2 (hu) 2022-01-28
CA3028315A1 (en) 2007-05-18
PH12021551194A1 (en) 2023-04-24
BRPI0618486A2 (pt) 2011-08-30
CN101336112B (zh) 2015-05-20
US11197889B2 (en) 2021-12-14
PL2684571T3 (pl) 2022-01-10
EP1951294B1 (en) 2019-12-25
US20060263337A1 (en) 2006-11-23
ES2884703T3 (es) 2021-12-10
US9962407B2 (en) 2018-05-08
CN101336112A (zh) 2008-12-31
IL249572A0 (en) 2017-02-28
WO2007056578A1 (en) 2007-05-18
EP2684571B1 (en) 2021-05-26
US20180055881A1 (en) 2018-03-01
AU2006311418A1 (en) 2007-05-18
EP2684571A1 (en) 2014-01-15
PL1951294T3 (pl) 2020-08-24
PH12015502169A1 (en) 2017-04-24
AU2006311418B2 (en) 2013-03-14
JP5897514B2 (ja) 2016-03-30
IL276705A (en) 2020-09-30
KR20080092336A (ko) 2008-10-15
US20210346429A1 (en) 2021-11-11
IL276705B (en) 2022-04-01
RU2497530C2 (ru) 2013-11-10
PT1951294T (pt) 2020-03-31
CA2628254C (en) 2023-06-20
PH12015502169B1 (en) 2022-02-11
CN104095878A (zh) 2014-10-15
CN104095878B (zh) 2020-01-21
PT2684571T (pt) 2021-08-30
RU2008122943A (ru) 2009-12-20
KR101423786B1 (ko) 2014-07-25
CA3028315C (en) 2023-09-05
CA2628254A1 (en) 2007-05-18
DK2684571T3 (da) 2021-08-30
EP3808373A1 (en) 2021-04-21
US20150118193A1 (en) 2015-04-30
IL191317A0 (en) 2008-12-29
JP6342880B2 (ja) 2018-06-13
NZ596022A (en) 2013-06-28

Similar Documents

Publication Publication Date Title
AU2006311418B2 (en) Immunomodulatory properties of multipotent adult progenitor cells and uses thereof
US20210228626A1 (en) Immunomodulatory properties of multipotent adult progenitor cells and uses thereof
AU2018202929B2 (en) Immunomodulatory properties of multipotent adult progenitor cells and uses thereof
AU2013273625B2 (en) Immunomodulatory properties of multipotent adult progenitor cells and uses thereof
HK1193978A (en) Immunomodulatory properties of multipotent adult progenitor cells and uses thereof
HK40046873A (en) Immunomodulatory properties of multipotent adult progenitor cells and uses thereof
HK1193978B (en) Immunomodulatory properties of multipotent adult progenitor cells and uses thereof
HK1123201B (en) Immunomodulatory properties of multipotent adult progenitor cells and uses thereof
HK1123201A (en) Immunomodulatory properties of multipotent adult progenitor cells and uses thereof
MX2008005940A (es) Propiedades inmunomoduladoras de celulas progenitoras adultas multipotentes y sus usos
HK1203058B (zh) 多潜能成体祖细胞的免疫调节特性及其用途

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 09 NOV 2016 BY CPA GLOBAL

Effective date: 20130927

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 NOV 2017 BY CPA GLOBAL

Effective date: 20160923

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 NOV 2018 BY CPA GLOBAL

Effective date: 20170929

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 NOV 2019 BY CPA GLOBAL

Effective date: 20180927

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 NOV 2020 BY CPA GLOBAL

Effective date: 20190926

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 NOV 2021 BY CPA GLOBAL

Effective date: 20200924

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 NOV 2022 BY CPA GLOBAL

Effective date: 20210924

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 NOV 2023 BY CPA GLOBAL

Effective date: 20220923

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 NOV 2024 BY CPA GLOBAL

Effective date: 20230928

LAPS Patent lapsed